{"entity":{"id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SOA101 in advanced solid tumours, run by Shine-On Biomedical Co., Ltd., now recruiting.","summary":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07055594 by Shine-On Biomedical Co., Ltd., with 76 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-02. Interventions recorded: SOA101.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07055594","url":"https://clinicaltrials.gov/study/NCT07055594"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07055594","phase":"1/2","setting":"A Phase I/IIa Dose-escalation, Dose-optimization and Dose Expansion Study to Evaluate the Safety and Preliminary Efficacy of Tri-specific Antibody (SOA101) in Subjects With Advanced Solid Tumors.","sponsor":"Shine-On Biomedical Co., Ltd.","enrolled":76,"outcomes":[]},"route":"/trials/nct07055594/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}